Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Biomea Fusion Inc (BMEA)

Biomea Fusion Inc (BMEA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 110,617
  • Shares Outstanding, K 72,299
  • Annual Sales, $ 0 K
  • Annual Income, $ -61,800 K
  • EBIT $ -84 M
  • EBITDA $ -82 M
  • 60-Month Beta -0.20
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.16

Options Overview Details

View History
  • Implied Volatility 150.70% (-57.07%)
  • Historical Volatility 83.21%
  • IV Percentile 30%
  • IV Rank 7.77%
  • IV High 791.65% on 11/20/25
  • IV Low 96.71% on 05/02/25
  • Expected Move (DTE 16) 0.3400 (22.22%)
  • Put/Call Vol Ratio 2.04
  • Today's Volume 4,094
  • Volume Avg (30-Day) 1,564
  • Put/Call OI Ratio 0.04
  • Today's Open Interest 48,598
  • Open Int (30-Day) 35,146
  • Expected Range 1.1900 to 1.8700

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.23
  • Number of Estimates 4
  • High Estimate $-0.12
  • Low Estimate $-0.43
  • Prior Year $-0.80
  • Growth Rate Est. (year over year) +71.25%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0700 +42.99%
on 03/24/26
1.5900 -3.77%
on 03/31/26
+0.1600 (+11.68%)
since 02/27/26
3-Month
1.0300 +48.54%
on 02/04/26
1.6600 -7.83%
on 01/15/26
+0.2100 (+15.91%)
since 12/26/25
52-Week
0.8719 +75.48%
on 11/21/25
3.0800 -50.32%
on 06/17/25
-0.7700 (-33.48%)
since 03/28/25

Most Recent Stories

More News
Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies

COVALENT-211 Phase II enrolling insulin-deficient type 2 diabetes patients  COVALENT-212 Phase II enrolling type 2 diabetes patients uncontrolled with a GLP-1 receptor agonist-based therapy Topline...

BMEA : 1.5300 (+15.91%)
Biomea Fusion Reports Full Year 2025 Financial Results and Corporate Highlights

Initiated two Phase II trials COVALENT-211 and COVALENT-212 (icovamenib in type 2 diabetes) with 26-week primary endpoint data anticipated in the fourth quarter of 2026 Completed 52-week follow-up from...

BMEA : 1.5300 (+15.91%)
Biomea Fusion Presents Phase II COVALENT-111 Data in Type 2 Diabetes at the 19th International Conference on Advanced Technologies & Treatments for Diabetes 2026

SAN CARLOS, Calif., March 14, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea,” “Biomea Fusion,” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today...

BMEA : 1.5300 (+15.91%)
Biomea Fusion to Participate at Upcoming Investor Conferences

SAN CARLOS, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Company” or “Company management”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today...

BMEA : 1.5300 (+15.91%)
Biomea Fusion Enters 2026 Focused on Executing Key Icovamenib and BMF-650 Milestones

Advancing icovamenib toward late-stage clinical development in two Phase II clinical trials in patients with insulin-deficient type 2 diabetes (“T2D”) and in T2D patients currently failing glucagon-like...

BMEA : 1.5300 (+15.91%)
Biomea Fusion to Present at the 44th Annual J.P. Morgan Healthcare Conference

SAN CARLOS, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that Mick Hitchcock, Ph.D., Interim...

BMEA : 1.5300 (+15.91%)
Biomea Fusion Announces KOL Presentation and Interview on Menin and Icovamenib at WCIRDC 2025

Key Opinion Leader, Dr. Ralph DeFronzo presents the “Future of Menin Inhibitors” and discusses icovamenib and its clinical results shared during WCIRDC 2025 in online interview SAN CARLOS, Calif.,...

BMEA : 1.5300 (+15.91%)
Biomea Fusion Presents COVALENT-111 Study Results at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

SAN CARLOS, Calif., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today...

BMEA : 1.5300 (+15.91%)
Biomea Fusion Announces Oral Presentation of Icovamenib at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

SAN CARLOS, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today...

BMEA : 1.5300 (+15.91%)
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

SAN CARLOS, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced...

BMEA : 1.5300 (+15.91%)

Business Summary

Biomea Fusion Inc. is a clinical-stage diabetes and obesity medicines company focused on the development of its oral small molecules, icovamenib and BMF-650. Biomea Fusion Inc., formerly known as BLOMEA FUSION, is based in Redwood City, California.

See More

Key Turning Points

3rd Resistance Point 1.9100
2nd Resistance Point 1.7500
1st Resistance Point 1.6400
Last Price 1.5300
1st Support Level 1.3700
2nd Support Level 1.2100
3rd Support Level 1.1000

See More

52-Week High 3.0800
Fibonacci 61.8% 2.2365
Fibonacci 50% 1.9760
Fibonacci 38.2% 1.7154
Last Price 1.5300
52-Week Low 0.8719

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.